Allogene Therapeutics, Inc. Deferred Tax Assets, Goodwill and Intangible Assets
Allogene Therapeutics, Inc. (ALLO) had Deferred Tax Assets, Goodwill and Intangible Assets of $10.10 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $10.10M.
- 2024-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $10.76M.
- 2023-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $14.52M.
- 2022-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $16.97M.
| Period end | Deferred Tax Assets, Goodwill and Intangible Assets | Deferred Tax Assets, Goodwill and Intangible Assets as first filed |
|---|---|---|
| 2025-12-31 | $10.10M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $10.76M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $14.52M 10-K · filed 2025-03-13 | |
| 2022-12-31 | $16.97M 10-K/A · filed 2024-03-14 | |
| 2021-12-31 | $14.09M 10-K/A · filed 2024-03-14 | $14.65M 10-K · filed 2022-02-23 |
| 2020-12-31 | $20.58M 10-K/A · filed 2024-03-14 | |
| 2019-12-31 | $22.77M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $23.09M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |